# **Product Datasheet**

# MITF Antibody (SPM290) [DyLight 755] NBP3-11527IR

Unit Size: 0.1 ml

Store at 4C in the dark.

www.novusbio.com



technical@novusbio.com

Protocols, Publications, Related Products, Reviews, Research Tools and Images at: www.novusbio.com/NBP3-11527IR

Updated 10/26/2023 v.20.1

Earn rewards for product reviews and publications.

Submit a publication at www.novusbio.com/publications Submit a review at www.novusbio.com/reviews/destination/NBP3-11527IR



## **NBP3-11527IR**

MITF Antibody (SPM290) [DyLig	ht 755]
Product Information	
Unit Size	0.1 ml
Concentration	Please see the vial label for concentration. If unlisted please contact technical services.
Storage	Store at 4C in the dark.
Clonality	Monoclonal
Clone	SPM290
Preservative	0.05% Sodium Azide
Isotype	IgG1 Kappa
Conjugate	DyLight 755
Purity	Protein A or G purified
Buffer	50mM Sodium Borate
<b>Product Description</b>	
Host	Mouse
Gene ID	4286
Gene Symbol	MITF
Species	Human, Mouse (Negative), Rat (Negative)
Reactivity Notes	Does not react with Mouse or Rat.
Specificity/Sensitivity	MITF (microphthalmia transcription factor) is a basic helix-loop-helix-leucine-zipper (bHLH-Zip) transcription factor that regulates the development and survival of melanocytes and retinal pigment epithelium, and also is involved in transcription of pigmentation enzyme genes such as tyrosinase TRP1 and TRP2. MITF has been shown to be phosphorylated by MAP kinase in response to c-kit activation, resulting in upregulation of MITF transcriptional activity. Mutations of the MITF gene are associated with the autosomal dominant hereditary deafness and pigmentation condition, Waardenburg Syndrome type 2A. Multiple isoforms of MITF exist, including MITF-A, MITF-B, MITF-C, MITF-H, and MITF-M, which differ in the amino-terminal domain and in their expression patterns. The MITF-M isoform is restricted to the melanocyte cell lineage. Anti-MITF, D5, recognizes a nuclear protein, which is expressed in the majority of primary and metastatic epithelioid malignant melanomas as well as in normal melanocytes, benign nevi and dysplastic nevi.
Immunogen	NH2 terminus fragment of human MITF (Uniprot: O75030)
Notes	DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
<b>Product Application Details</b>	
Applications	Immunohistochemistry, Immunohistochemistry-Paraffin
Recommended Dilutions	Immunohistochemistry, Immunohistochemistry-Paraffin

<b>Product Application Details</b>	
Applications	Immunohistochemistry, Immunohistochemistry-Paraffin
Recommended Dilutions	Immunohistochemistry, Immunohistochemistry-Paraffin
Application Notes	Optimal dilution of this antibody should be experimentally determined.





# Novus Biologicals USA

10730 E. Briarwood Avenue Centennial, CO 80112

USA

Phone: 303.730.1950 Toll Free: 1.888.506.6887

Fax: 303.730.1966

nb-customerservice@bio-techne.com

#### **Bio-Techne Canada**

21 Canmotor Ave Toronto, ON M8Z 4E6

Canada

Phone: 905.827.6400 Toll Free: 855.668.8722 Fax: 905.827.6402

canada.inquires@bio-techne.com

#### **Bio-Techne Ltd**

19 Barton Lane Abingdon Science Park Abingdon, OX14 3NB, United Kingdom Phone: (44) (0) 1235 529449

Free Phone: 0800 37 34 15 Fax: (44) (0) 1235 533420 info.EMEA@bio-techne.com

#### **General Contact Information**

www.novusbio.com

Technical Support: nb-technical@bio-

techne.com

Orders: nb-customerservice@bio-techne.com

General: novus@novusbio.com

## **Products Related to NBP3-11527IR**

NBP1-43319IR-0.5ml Mouse IgG1 Kappa Isotype Control (P3.6.2.8.1) [DyLight 755]

H00004286-P02-2ug Recombinant Human MITF GST (N-Term) Protein

210-TA-005 TNF-alpha [Unconjugated]
NBP2-09070 MITF Overexpression Lysate

#### Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP3-11527IR

Earn gift cards/discounts by submitting a publication using this product: www.novusbio.com/publications

